K. Asghar and A. Loya, “INDOLEAMINE 2,3 DIOXYGENASE AS AN IMMUNOTHERAPEUTIC TARGET BRINGS A NEW HOPE FOR CANCER PATIENTS”, J Cancer Allied Spec, vol. 4, no. 3, Sep. 2018.